Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese

Journal of Hepatology

Volumn 39, Issue 6, 2003, Pages 967-971

  Dixon, John B ^a   Bhathal, Prithi S ^b   Jonsson, Julie R ^c   Dixon, Andrew F ^a   Powell, Elizabeth E ^c   O'Brien, Paul E ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Fibrosis; Non alcoholic fatty liver disease; Obese patients

Indexed keywords

ANGIOTENSIN; ANGIOTENSINOGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FATTY LIVER; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; HYPOTHESIS; LAPAROSCOPIC SURGERY; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; RISK; RISK FACTOR;

EID: 0348134731     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00459-8     Document Type: Article

References (29)

1. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999;19:129-140.
2. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in non-alcoholic fatty liver disease. Gastroenterology 2002;122:274-280.
3. Day C. CD14 promoter polymorphism associated with risk of NASH. J Hepatol 2002;36:21.
4. Powell EE, Edwards-Smith CJ, Hay JL et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-833.
5. Dixon JB, Bhathal PS, O'Brien PE. Non-alcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
6. Noble NA, Border WA. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 1997;17:455-466.
7. Bedossa P, Paradis V. Transforming growth factor-beta (TGF-beta): a key-role in liver fibrogenesis. J Hepatol 1995;22:37-42.
8. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-1020.
9. Lacha J, Hubacek JA, Potmesil P, Viklicky O, Malek I, Vitko S. TGF-beta I gene polymorphism in heart transplant recipients - effect on renal function. Ann Transplant 2001;6:39-43.
10. Li B, Khanna A, Sharma V, Singh T, Suthanthiran M, August P. TGF-beta1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 1999;33:271-275.
11. Gewaltig J, Mangasser-Stephan K, Gattung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta 2002;316:83-94.
12. Inoue I, Nakajima T, Williams CS et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997;99:1786-1797.
13. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-461.
14. Hahn AW, Resink TJ, Bernhardt J, Ferracin F, Buhler FR. Stimulation of autocrine platelet - derived growth factor AA-homodimer and transforming growth factor beta in vascular smooth muscle cells. Biochem Biophys Res Commun 1991;178:1451-1458.
15. Jonsson JR, Clouston AD, Ando Y et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001;121:148-155.
16. James J, Bosch KS, Zuyderhoudt FM, Houtkooper JM, van Gool J. Histophotometric estimation of volume density of collagen as an indication of fibrosis in rat liver. Histochemistry 1986;85:129-133.
17. Vyberg M, Leth P. Ubiquitin: an immunohistochemical marker of Mallory bodies and alcoholic liver disease. APMIS Suppl 1991;23:46-52.
18. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
19. Lee RG. Alcoholic and nonalcoholic steatohepatitis. In: JR Bloomer ZR, KG Ishak, ed. Clinical and pathological correlations in liver disease: Approaching the next millenium. Washington, DC: American Association for the Study of Liver Disease 1998;2748-2783.
20. Lee RG. Non-alcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology 1995;21:1742-1743.
21. Lympany PA, Avila JJ, Mullighan C, Marshall S, Welsh KI, du Bois RM. Rapid genotyping of transforming growth factor beta1 gene polymorphisms in a UK Caucasoid control population using the polymerase chain reaction and sequence-specific primers. Tissue Antigens 1998;52:573-578.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
23. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program [letter]. Diabetes Care 1998;21:2191-2192.
24. SPSS I, SPSS for Windows, 10.0.5 Edition. Chicago, IL, USA: SPSS. Inc; 1999.
25. O'Brien P, Brown W, Smith A, McMurrick P, Stephens M. Prospective study of a laparoscopically placed, adjustable gastric band in the treatment of morbid obesity. Br J Surg 1999;86:113-118.
26. Yoshiji H, Kuriyama S, Yoshii J et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-750.
27. Paizis G, Gilbert RE, Cooper ME et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001;35:376-385.
28. Wei HS, Li DG, Lu HM et al. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CC1(4). World J Gastroenterol 2000;6:540-545.
29. Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997;17:467-491.